Physician profile
Hans Knopp
NPI 1639506967
$10,975.05
in general payments reported to CMS, 2019-2025
35 companies · $2,759 in 2025
The $2,759 reported for 2025 was more than what 89% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $251 · 2021: $1,195 · 2022: $1,067 · 2023: $2,439 · 2024: $2,288 · 2025: $2,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,486.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,715.49 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Patient Trial Kit |
| Spr Therapeutics, INC | $1,086.74 | 2021-2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $948.26 | 2022-2025 | Relistor |
| Abbvie INC. | $836.61 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $702.45 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $592.19 | 2019-2025 | Ztlido |
| Azurity Pharmaceuticals, INC. | $587.78 | 2023-2025 | Horizant, Horizant |
| Allergan, INC. | $418.26 | 2019-2021 | |
| Si-Bone, INC. | $356.89 | 2021-2025 | |
| Saluda Medical Americas, INC. | $350.50 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $347.42 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Valinor Pharma, LLC | $271.00 | 2023-2025 | Movantik |
| Abbott Laboratories | $254.09 | 2019-2022 | |
| Nevro Corp. | $211.01 | 2020-2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $176.67 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $141.76 | 2023-2024 | Mild Device Kit |
| Pfizer INC. | $122.89 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $119.42 | 2023-2024 | Dysport |
| Stratus Medical, LLC | $116.67 | 2022-2023 | Nimbus |
| Ibsa Pharma INC. | $93.56 | 2023-2024 | Tirosint, Licart, Tirosint |
| Merz Pharmaceuticals, LLC | $92.62 | 2023-2024 | Xeomin |
| Arbor Pharmaceuticals, INC. | $64.04 | 2019-2022 | |
| Avanos Medical | $59.41 | 2019 | |
| Grt US Holding, INC. | $43.35 | 2022 | |
| Nalu Medical, INC. | $37.99 | 2022-2024 | Nalu Neurostimulation System |
| Neurometrix INC | $32.44 | 2023 | |
| Curonix LLC | $29.00 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $27.52 | 2019-2020 | |
| Globus Medical, INC. | $24.81 | 2025 | Vyrsa V1 |
| Ultragenyx Pharmaceutical INC. | $23.06 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.02 | 2022 | |
| Redhill Biopharma INC. | $22.05 | 2021 | |
| Averitas Pharma INC. | $20.27 | 2024 | Qutenza |
| Bioventus LLC | $12.95 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Knopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.